Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PRCP | P42785 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 4/20 | 0.39 |
| ▸ | CTSC | P53634 | 3/20 | 0.39 |
| ▸ | HTR2B | P41595 | 2/20 | 0.39 |
| ▸ | TLR2 | O60603 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29540363 | 0.90 | TERT (0.45) | TERTMEN1KMT2APRCPKDM4E | |
| SCHEMBL30193515 | 0.88 | TERT (0.50) | TERTMEN1KMT2APRCPKDM4E | |
| SCHEMBL29630597 | 0.87 | TERT (0.47) | TERTMEN1KMT2APRCPKDM4E | |
| SCHEMBL29805502 | 0.87 | TERT (0.45) | TERTMEN1KMT2APRCPKDM4E | |
| SCHEMBL31611748 | 0.86 | TERT (0.43) | TERTMEN1KMT2APRCPKDM4E | |
| SCHEMBL29570472 | 0.86 | TERT (0.51) | TERTMEN1KMT2APRCPKDM4E | |
| SCHEMBL30193538 | 0.86 | MEN1 (0.48) | TERTMEN1KMT2APRCPKDM4E | |
| SCHEMBL26389273 | 0.86 | TERT (0.48) | TERTMEN1KMT2APRCPKDM4E | |
| SCHEMBL30487458 | 0.86 | TERT (0.51) | TERTMEN1KMT2APRCPKDM4E | |
| SCHEMBL25365110 | 0.86 | MEN1 (0.48) | TERTMEN1KMT2APRCPDPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11891457-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-06 | — | — | US | disclosed |
| CN-117203334-A | Epigenetic gene modulation for the treatment of neurological disorders and pain | 纳维加治疗公司 | 2023-12-08 | — | — | CN | disclosed |
| EP-4284927-A2 | EPIGENETIC GENE REGULATION TO TREAT NEUROLOGICAL DISEASES AND PAIN | Navega Therapeutics, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| WO-2023150693-A2 | NEUREGULIN-4 ANALOGS AND METHODS OF USING THEREOF IN DISEASE TREATMENT | AVEXEGEN THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2022165362-A2 | EPIGENETIC GENE REGULATION TO TREAT NEUROLOGICAL DISEASES AND PAIN | NAVEGA THERAPEUTICS, INC. (US) | 2022-08-04 | — | — | WO | disclosed |
| EP-3974563-A1 | CYCLIC PEPTIDES | Chugai Seiyaku Kabushiki Kaisha (JP) | 2022-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891457-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | TERT 2851/4885MEN1 394/4885KMT2A 4608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.